Search

Your search keyword '"Lok, Catherine"' showing total 276 results
Start Over Author "Lok, Catherine"
Sorry, I don't understand your search. ×
276 results on '"Lok, Catherine"'

1. Elastic fiber alterations and calcifications in calcific uremic arteriolopathy

Author

Colboc, Hester, Moguelet, Philippe, Bazin, Dominique, Letavernier, Emmanuel, Sun, Chenyu, Chessel, Anatole, Carvalho, Priscille, Lok, Catherine, Dillies, Anne-Sophie, Chaby, Guillaume, Maillard, Hervé, Kottler, Diane, Goujon, Elisa, Jurus, Christine, Panaye, Marine, Tang, Ellie, Courville, Philippe, Boury, Antoine, Monfort, Jean-Benoit, Chasset, François, Senet, Patricia, and Schanne-Klein, Marie-Claire

Published
2023
Full Text
View/download PDF

2. Asymmetric periflexural exanthem of childhood and influenza virus infection.

Author

Cohen-Sors, Raphaella, Dadban, Ali, Pezron, Juliette, and Lok, Catherine

Subjects
unilateral laterothoracic exanthem, influenza A
Abstract

Asymmetric periflexural exanthem of childhood (APEC) is a self-limited disease characterized by unilateral exanthem. The etiology is unknown, but a viral agent is suspected. Most often there is no formal proof of an associated viral etiology, but several associations between APEC and some viruses have been described. We report a 2-year-old girl with APEC associated with influenza A. This case allows us to provide an additional argument on a probable viral etiology of APEC and a possible etiologic role of influenza A.

Published
2020

3. Iatrogenic cutaneous graft versus host disease.

Author

Cohen-Sors, Raphaella, Arnault, Jean-Philippe, Attencourt, Christophe, Charbonnier, Amandine, Adas, Alanoud, Chaby, Guillaume, and Lok, Catherine

Subjects
localized cutaneous GVHD, verruca vulgaris, Koebner Phenomenon
Abstract

A 65-year-old man with acute myeloid leukemia 6 was treated by bone marrow allograft, developed a systemic classic chronic graft versus host disease with hepatic, rheumatologic, ophthalmic, and muco-cutaneous involvement. He received systemic corticosteroid, ruxolitinib and extracorporeal photopheresis which resulted in complete remission. During follow-up the patient presented with viral cutaneous warts on his neck and submandibular area. After various subsequent topical treatments, he developed localized cutaneous GVHD without any general GVHD reactivation symptoms. To the best of our knowledge, there has been no description in the literature of a graft versus host disease developing after local immunomodulatory or cytotoxic treatments. Topical therapies are commonly used by dermatologists for superficial skin cancers and some viral skin lesions, in high risk populations such as organ transplant patients with regular follow-up.Practitioners should be made aware of a possible localized cutaneous GVHD reactivation induced by Koebner phenomenon after local therapy.

Published
2020

4. Chemotherapy-induced leg ulcers: a case series.

Author

Rousselot, Marion, Mahé, Emmanuel, Senet, Patricia, Rousselot, Philippe, Baudot, Nathalie, Moawad, Sandra, Schoeffler, Amélie, Goujon, Elisa, Villemur, Béatrice, Lok, Catherine, Cuny, Jean-François, Guern, Aurore Le, Sigal, Michèle-Léa, and Tella, Emilie

Abstract

Objective: New therapeutic classes of chemotherapy, including tyrosine kinase inhibitors (TKIs), are being developed, leading to unexpected cutaneous side-effects. The aim was to analyse the development of leg ulcers (LUs) associated with chemotherapy to identify their characteristics and management. Method: A retrospective multicentre study was conducted across nine French dermatology departments and one haematology department. We collected information on cancer history, cofactors of LUs, and management and evolution of the LUs. Results: The study included 45 patients divided into three groups: hydroxyurea treatment; targeted therapies including TKIs; and taxane treatment. Certain factors were common for arteriovenous leg ulcers, especially advanced age, the frequency of vascular cofactors and the painful nature of the ulcer; however, significant differences were apparent. In particular, the delay between the introduction of chemotherapy and the beginning of the LU. The delay in appearance of the LU was shorter for patients in the taxanes and TKIs groups versus patients treated with hydroxyurea (hydroxyurea versus taxanes: p<0.0001; hydroxyurea versus TKIs: p=0.004). Following the appearance of the LU, treatment was normally stopped (88%), with cicatrisation (91%) occurring within a period of 4.6 months on average. These results confirm the known association of hydroxyurea and LUs; however, other chemotherapies, including targeted therapies and taxanes, appear to be involved. Conclusion: Prescribers should be made aware of skin side-effects of chemotherapies and the risk–benefit of discontinuing chemotherapy for ulcer healing should be raised. Closer monitoring to control identified cofactors of LUs is required in patients receiving this type of chemotherapy, especially if they have LU-predisposing factors. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Acrodermatitis continua of Hallopeau response to optimized biological therapy

Author

Adas, Alanoud, Dadban, Ali, Arnault, Jean-Philippe, Chaby, Guillaume, and Lok, Catherine

Subjects
Acrodermatitis of hallopeau, pustular psoriasis, biotherapy, optimization, etanercept, ustekinumab
Abstract

Acrodermatitis continua of Hallopeau, first described in 1890, is an uncommon variant of pustular psoriasis. It presents as a sterile pustular eruption of the tips of fingers and toes. The condition has a chronic, relapsing course and is often resistant to many anti-psoriatic therapies. In the following case, we present our experience of etanercept use in a 61-year-old man. Although initial therapy with high-dose etanercept achieved a rapid, sustained response and remission, the lesions relapsed a few months into a lower, maintenance dosage. This result prompted the use a second biotherapeutic agent ustekinumab, which resulted in complete remission, but required a higher dosage than recommended with reduced dosing intervals.

Published
2019

6. Nailfold dermoscopy predicts the absence of a capillaroscopy sclerodermic pattern: The multicentre, prospective VASCUL‐R trial.

Author

Monfort, Jean‐Benoît, Klejtman, Tiffany, Lazareth, Isabelle, Kottler, Diane, Blaise, Sophie, Imbert, Bernard, Chaby, Guillaume, Lok, Catherine, Maillard, Hervé, Beneton, Nathalie, Journet‐Tollhupp, Julie, Goujon, Elisa, Jacquin, Aurélien, Tella, Emilie, Mboup, Bassirou, Vicaut, Eric, and Senet, Patricia

Subjects
RAYNAUD'S disease, DERMOSCOPY, CAPILLAROSCOPY, DERMATOLOGISTS, HEMORRHAGE, CAPILLARIES
Abstract

Background: Nailfold capillaroscopy is recommended to diagnose primary or secondary Raynaud's phenomenon (RP). Capillaroscopy is normal in primary RP, which is the most frequent. Screening for RP capillary anomalies with nailfold dermoscopy has been promising. Objective: To determine whether normal nailfold dermoscopy—based on the absence of five criteria that define a sclerodermic pattern—is able to predict normal capillaroscopy with good positive‐predictive value (PPV). Methods: Prospective, 2‐phase (monocentre and multicentre) study on patients at first consultation for RP undergoing nailfold video capillaroscopy (NVC) and nailfold dermoscopy by two different 'blinded' trained observers, respectively, a vascular specialist and a dermatologist, not familiar with capillaroscopy. The five criteria noted were as follows: disorganization, megacapillaries, low capillary density, avascular areas and haemorrhages. Results: Based on 105 patients, the dermoscopy PPV for a normal NVC was 100% (p = 0.015), with 37.9% sensitivity, when no criterion was observed. Excluding haemorrhages, the PPV remained 100% (p < 0.0001), with sensitivity rising to 73.7% and 100% specificity. Conclusions: Normal nailfold dermoscopy with the absence of four easy‐to‐observe criteria predicts normal NVC with an excellent PPV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

Author

Eggermont, Alexander M.M., Rutkowski, Piotr, Dutriaux, Caroline, Hofman-Wellenhof, Rainer, Dziewulski, Peter, Marples, Maria, Grange, Floren, Lok, Catherine, Pennachioli, Elisabetta, Robert, Caroline, van Akkooi, Alexander C.J., Bastholt, Lars, Minisini, Alessandro, Marshall, Ernest, Salès, François, Grob, Jean-Jacques, Bechter, Oliver, Schadendorf, Dirk, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Testori, Alessandro A.E.

Published
2020
Full Text
View/download PDF

8. Generalized pruritus in dysmetabolic hyperferritinemia treated by phlebotomy

Author

Brigant, Fanny, Hautefeuille, Vincent, Dadban, Ali, Lok, Catherine, Nguyen-Khac, Eric, and Chaby, Guillaume

Subjects
pruritus, dysmetabolic, hyperferritinemia, phlebotomy, metabolic syndrome, hepatic iron overload
Abstract

This paper describes a case of pruritus caused by dysmetabolic hyperferritinemia treated by multiple phlebotomies.A 63-year-old man was followed for generalized pruritus, which was resistant to the usual treatments. He presented with metabolic syndrome. Physical examination showed only excoriations and lichenification on the skin. The serum ferritin was high at 1043 ng/ml, with transferrin saturation at 67%. The other biological investigations and genetic tests for hemochromatosis were negative.In spite of the dietary measures, the ferritin level was still high (853ng/ml). Magnetic resonance imaging confirmed hepatic iron overload.The association of hyperferritinemia, hepatic iron overload, and metabolic syndrome led to the diagnosis of dysmetabolic hyperferritinemia.Phlebotomies are an unusual treatment, but because the pruritus and hyperferritinemia were still present, phlebotomy wasinitiated. After 19 months, the patient reported improvement of his pruritus and normalization of ferritin levels.

Published
2015

13. Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

Author

Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, Lok, Catherine, Université de Picardie Jules Verne (UPJV), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie (CHU de Dijon), UMR 1253 IBrain Imagerie & Cerveau Equipe 3 'Imagerie, Biomarqueurs & Thérapie' (IBT), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de dermatologie [CHU d'Amiens-Picardie]

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy.

Published
2023
Full Text
View/download PDF

14. Une dermoscopie périunguéale normale prédit l’absence de paysage sclérodermique en capillaroscopie

Author

Monfort, Jean-Benoît, primary, Klejtman, Tiffany, additional, Vicaut, Eric, additional, Lazareth, Isabelle, additional, Kottler, Diane, additional, Blaise, Sophie, additional, Imbert, Bernard, additional, Chaby, Guillaume, additional, Lok, Catherine, additional, Maillard, Hervé, additional, Beneton, Nathalie, additional, Journet, Julie, additional, Goujon, Elisa, additional, Jacquin, Aurélien, additional, Tella, Emilie, additional, and Senet, Patricia, additional

Published
2023
Full Text
View/download PDF

18. Prise en charge des érythermalgies : étude rétrospective multicentrique

Author

Monfort, Jean-Benoît, Lazareth, Isabelle, Blaise, Sophie, Chaby, Guillaume, Lok, Catherine, and Senet, Patricia

Abstract

L’érythermalgie est un acrosyndrome vasculaire rare se manifestant par des douleurs et un érythème paroxystiques, déclenchés par le chaud et calmés par le froid. Les objectifs de cette étude étaient d’évaluer les examens paracliniques utiles au diagnostic étiologique et d’identifier l’efficacité et la tolérance de(s) traitement(s) prescrits dans l’érythermalgie.

Published
2025
Full Text
View/download PDF

24. A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study

Author

Joly, Pascal, Roujeau, Jean-Claude, Benichou, Jacques, Delaporte, Emmanuel, D'Incan, Michel, Dreno, Brigitte, Bedane, Christophe, Sparsa, Agnes, Gorin, Isabelle, Picard, Catherine, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Lok, Catherine, Guillaume, Jean-Claude, Doutre, Marie-Sylvie, Richard, Marie-Aleth, Caux, Frédéric, Prost, Catherine, Plantin, Patrice, Chosidow, Olivier, Pauwels, Christine, Maillard, Hervé, Saiag, Philippe, Descamps, Vincent, Chevrant-Breton, Jacqueline, Dereure, Olivier, Hellot, Marie-France, Esteve, Eric, and Bernard, Philippe

Published
2009
Full Text
View/download PDF

25. French recommendations for the management of systemic sclerosis

Author

Hachulla, Eric, Agard, Christian, Allanore, Yannick, Avouac, Jérôme, Bader-Meunier, Brigitte, Belot, Alexandre, Berezne, Alice, Bouthors, Anne-Sophie, Condette-Wojtasik, Geraldine, Constans, Joël, de Groote, Pascal, Diot, Elisabeth, Dumas, Florence, Jego, Patrick, Joly, Francisca, Launay, David, Le Guern, Veronique, Le Quintrec, Janine-Sophie, Lescaille, Géraldine, Meune, Christophe, Moulin, Bruno, Nguyen, Christelle, Omeish, Nadine, Pene, Frédéric, Richard, Marie-Aleth, Rochefort, Juliette, Roren, Alexandra, Sitbon, Olivier, Sobanski, Vincent, Truchetet, Marie-Elise, Mouthon, Luc, Bayen, Marc, Bergot, Emmanuel, Berthier, Sabine, Bosco, Julia, Bouhnik, Yoram, Chaigne, Benjamin, Cottin, Vincent, Crestani, Bruno, Deligny, Christophe, Descroix, Vianney, Farge, Dominique, Godard, Dominique, Granel, Brigitte, Guilpain, Philippe, Imbert, Bernard, Le Quellec, Alain, Lega, Christophe, Lok, Catherine, Maillard, Hélène, Martin, Thierry, Pugnet, Grégory, Queyrel, Viviane, Raffray, Loïc, Rilliard, Frédéric, Romier, Mélanie, Schuller, Laurence, Servettaz, Amélie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pontchaillou [Rennes], Hôpital Beaujon [AP-HP], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Avicenne [AP-HP], CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
medicine.medical_specialty, Poor prognosis, Hypertension, Pulmonary, Scleroderma Renal Crisis, Aucun, Connective tissue, MESH: Skin Diseases, Favorable prognosis, Recommendations, Skin Diseases, Scleroderma, MESH: Scleroderma, Systemic, 03 medical and health sciences, 0302 clinical medicine, MESH: Skin, Fibrosis, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Generalized Disease, Position Statement, skin and connective tissue diseases, Genetics (clinical), Skin, 030203 arthritis & rheumatology, Scleroderma, Systemic, MESH: Humans, integumentary system, MESH: Hypertension, Pulmonary, business.industry, Interstitial lung disease, General Medicine, medicine.disease, Dermatology, Treatment, medicine.anatomical_structure, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Medicine, Systemic sclerosis, business, Lung Diseases, Interstitial, MESH: Lung Diseases, Interstitial
Abstract

Systemic sclerosis (SSc) is a generalized disease of the connective tissue, arterioles, and microvessels, characterized by the appearance of fibrosis and vascular obliteration. There are two main phenotypical forms of SSc: a diffuse cutaneous form that extends towards the proximal region of the limbs and/or torso, and a limited cutaneous form where the cutaneous sclerosis only affects the extremities of the limbs (without passing beyond the elbows and knees). There also exists in less than 10% of cases forms that never involve the skin. This is called SSc sine scleroderma. The prognosis depends essentially on the occurrence of visceral damage and more particularly interstitial lung disease (which is sometimes severe), pulmonary arterial hypertension, or primary cardiac damage, which represent the three commonest causes of mortality in SSc. Another type of involvement with poor prognosis, scleroderma renal crisis, is rare (less than 5% of cases). Cutaneous extension is also an important parameter, with the diffuse cutaneous forms having less favorable prognosis.

Published
2021
Full Text
View/download PDF

26. Nécrobiose lipoïdique : 33 cas

Author

Tella, Emilie, primary, Jacquin, Aurélien, additional, Maillard, Hervé, additional, Senet, Patricia, additional, Kottler, Diane, additional, Goujon, Elisa, additional, Modiano, Philippe, additional, Le Guern, Aurore, additional, Lok, Catherine, additional, and Mahé, Emmanuel, additional

Published
2021
Full Text
View/download PDF

27. Étude comparative de la mortalité des patients atteints de pemphigus selon l’utilisation du rituximab ou de traitements conventionnels

Author

Aldahmash, Abdulaziz, primary, Cotten, Caroline, additional, Hebert, Vivien, additional, Gillibert, Andre, additional, Duvert-Lehembre, Sophie, additional, Debarbieux, Sebastien, additional, Chosidow, Olivier, additional, Dupin, Nicolas, additional, Alexandre, Marina, additional, Tancrede-Bohin, Emmanuelle, additional, Picard-Dahan, Catherine, additional, Gusdorf, Laurence, additional, Lok, Catherine, additional, Doutre, Marie-Sylvie, additional, Konstantinou, Maria Polina, additional, Chiaverini, Christine, additional, Misery, Laurent, additional, Dupuy, Alain, additional, Quereux, Gaelle, additional, Morice, Cecile, additional, D’incan, Michel, additional, Bedane, Christophe, additional, Cordel, Nadege, additional, Dereure, Olivier, additional, Machet, Laurent, additional, Audran, Martine Avenel, additional, Richard-Lallemand, Marie-Aleth, additional, Vabres, Pierre, additional, Labeille, Bruno, additional, Beneton, Nathalie, additional, and Joly, Pascal, additional

Published
2021
Full Text
View/download PDF

28. Caractérisation des altérations des fibres élastiques et des calcifications par microscopie multiphoton au cours de la calciphylaxie urémique

Author

Colboc, Hester, primary, Moguelet, Philippe, additional, Bazin, Dominique, additional, Carvalho, Priscille, additional, Dillies, Anne-Sophie, additional, Lok, Catherine, additional, Chaby, Guillaume, additional, Maillard, Hervé, additional, Kottler, Diane, additional, Goujon, Elisa, additional, Jurus, Christine, additional, Panaye, Marine, additional, Courville, Philippe, additional, Monfort, Jean-Benoit, additional, Chasset, François, additional, Boury, Antoine, additional, Combes, Christele, additional, Letavernier, Emmanuel, additional, Schanne-Klein, Marie-Claire, additional, and Senet, Patricia, additional

Published
2021
Full Text
View/download PDF

29. Infection à Clostridium difficile et colite auto-immune sous immunothérapie dans le mélanome : étude rétrospective de 18 cas

Author

Vuillamy, Chloé, primary, Arnault, Jean-Philippe, additional, Fumery, Mathurin, additional, Mortier, Laurent, additional, Monestier, Sandrine, additional, Mansard, Sandrine, additional, Bens, Guido, additional, Duval-Modeste, Anne-Bénédicte, additional, Funck-Brentano, Elisa, additional, Jeudy, Géraldine, additional, Machet, Laurent, additional, Chaby, Guillaume, additional, Dadban, Ali, additional, and Lok, Catherine, additional

Published
2021
Full Text
View/download PDF

32. Clostridium difficileinfection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

Author

Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, and Lok, Catherine

Abstract

Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor–induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficileinfection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficileshould be carried out for all patients with diarrhea who are being treated with immunotherapy.

Published
2023
Full Text
View/download PDF

35. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome

Author

Bubien, Virginie, Bonnet, Françoise, Brouste, Veronique, Hoppe, Stéphanie, Barouk-Simonet, Emmanuelle, David, Albert, Edery, Patrick, Bottani, Armand, Layet, Valérie, Caron, Olivier, Gilbert-Dussardier, Brigitte, Delnatte, Capucine, Dugast, Catherine, Fricker, Jean-Pierre, Bonneau, Dominique, Sevenet, Nicolas, Longy, Michel, Caux, Frédéric, Abramowicz, Marc, Bessis, Didier, Bieth, Eric, Bérard, Valérie Bonadonaon, Bonnetblanc, Jean-Marie, Demange, Liliane, Feillet, François, Frebourg, Thierry, Giraud, Sophie, Giurgea, Irina, Heron, Delphine, Holder, Muriel, Journel, Hubert, Julia, Sophie, Kacem, Maha, Lejeune, Sophie, Leprat, Frédéric, Leroux, Dominique, Lok, Catherine, Lortholary, Alain, Lyonnet, Stanislas, Margueritte, Geneviève, Mauillon, Jacques, Mazereeuw-Hautier, Juliette, Odent, Sylvie, Penet, Clotilde, Philippe, Anne, Plauchu, Henri, Plessismenceau, Ghislaine, Plouvieron, Emmanuel, Richard, Marie-Aleth, Saadi, Abdelkrim, Saurin, Jean-Christophe, Tinat, Julie, Vabres, Pierre, Van Maldergemteil, Lionel, Vennin, Philippe, and Weiller, Pierre-Jean

Published
2013
Full Text
View/download PDF

36. Prognostic Factors of Paraneoplastic Pemphigus

Author

Leger, Sandy, Picard, Damien, Ingen-Housz-Oro, Saskia, Arnault, Jean-Philippe, Aubin, François, Carsuzaa, Francis, Chaumentin, Gilles, Chevrant-Breton, Jacqueline, Chosidow, Olivier, Crickx, Béatrice, D’incan, Michel, Dandurand, Michel, Debarbieux, Stéphane, Delaporte, Emmanuel, Dereure, Olivier, Doutre, Marie-Sylvie, Guillet, Gérard, Jullien, Denis, Kupfer, Ingrid, Lacour, Jean-Philippe, Leonard, Fabienne, Lok, Catherine, Machet, Laurent, Martin, Ludovic, Paul, Carle, Pignon, Jean-Michel, Robert, Caroline, Thomas, Luc, Weiller, Pierre-Jean, Ferranti, Vincent, Gilbert, Danièle, Courville, Philippe, Houivet, Estelle, Benichou, Jacques, and Joly, Pascal

Published
2012
Full Text
View/download PDF

39. Les auteurs

Author

Allenet, Benoît, primary, Al Hajj-Karnib, Amal, additional, Angoulvant, Denis, additional, Antignac, Marie, additional, Armoiry, Xavier, additional, Aulagner, Gilles, additional, Baguet, Jean-Philippe, additional, Barreteau, Hélène, additional, Baudrant, Magalie, additional, Bedouch, Pierrick, additional, Bertrand, Marie-Anne, additional, Bolon-Larger, Magali, additional, Bonaz, Bruno, additional, Bonnefoy, Éric, additional, Boulieu, Roselyne, additional, Boyer-Grand, Anne, additional, Brazier, Michel, additional, Brudieu, Étienne, additional, Brunet, Philippe, additional, Buyse, Marion, additional, Calop, Jean, additional, Calop, Nathalie, additional, Caron, Philippe, additional, Cassat, Claude, additional, Cavicchi, Maryan, additional, Chapuis, Claire, additional, Chaumard, Natacha, additional, Chopineau, Jean, additional, Claerbout, Jean-François, additional, Clerc, Bertrand, additional, Contreras, Rémy, additional, Décaudin, Bertrand, additional, Desbiez, Françoise, additional, Desplaces, Nicole, additional, Dine, Thierry, additional, Djian, Cécile, additional, Derouesné, Christian, additional, Desablens, Françoise, additional, Dode, Xavier, additional, Ducharme, Murray P., additional, Dupuis, Antoine, additional, Fardellone, Patrice, additional, Farinotti, Robert, additional, Faure, Pierre, additional, Federspiel, Isabelle, additional, Fernandez, Christine, additional, Ferreira, Ema, additional, Francois, Éric, additional, Franchon, Émilie, additional, Germain, Emmanuel, additional, Gourdier, Bertrand, additional, Goujard, Cécile, additional, Grellet, Jean, additional, Guichard, Sylvie, additional, Hadri, Nassira, additional, Hulin, Anne, additional, Kaulek-Westeel, Virginie, additional, Laederich, Joëlle, additional, Lebargy, François, additional, Legat-Fagnoni, Christine, additional, Leverge, Roger, additional, Limat, Samuel, additional, Lok, Catherine, additional, Luyckx, Michel, additional, Madelaine, Isabelle, additional, Mailhot, Claude, additional, Mallet, Louise, additional, Marteau, Philippe, additional, Massias, Laurent, additional, Medjoub, Mehdi, additional, Mornex, Jean-François, additional, Odou, Pascal, additional, Pharand, Chantal, additional, Ragon, Alain, additional, Raignoux, Cécile, additional, Ratsimbazafy, Voa, additional, Rey, Chrystelle, additional, Richard, Denis, additional, Robert, Hugues, additional, Roulet, Lucien, additional, Sallerin, Brigitte, additional, Sautou-Miranda, Valérie, additional, Saux, Marie-Claude, additional, Senon, Jean-Louis, additional, Singlas, Éric, additional, Somda, Frédéric, additional, Steinmetz, Jean-Philippe, additional, Sylvoz, Nathalie, additional, Taburet, Anne-Marie, additional, Tacco, Frédéric, additional, Talbert, Marc, additional, Tauveron, Igor, additional, Thirion, Daniel J.G., additional, Thuong-Guyot, Marie, additional, Trivin, Caroline, additional, Venisse, Nicolas, additional, Vincent, Isabelle, additional, Williamson, David, additional, Wolff, Michel, additional, and Woronoff-Lemsi, Marie-Christine, additional

Published
2008
Full Text
View/download PDF

47. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

Author

Eggermont, Alexander A.M.M., Rutkowski, Piotr, Dutriaux, Caroline, Hofman-Wellenhof, Rainer, Dziewulski, Peter, Marples, Maria, Grange, Floren, Lok, Catherine, Pennachioli, Elisabetta, Robert, Caroline, van Akkooi, Alexander A.C.J., Bastholt, Lars, Minisini, Alessandro Marco, Marshall, Ernest, Sales, François, Grob, Jean Jacques, Bechter, Oliver, Schadendorf, Dirk, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Testori, Alessandro, Eggermont, Alexander A.M.M., Rutkowski, Piotr, Dutriaux, Caroline, Hofman-Wellenhof, Rainer, Dziewulski, Peter, Marples, Maria, Grange, Floren, Lok, Catherine, Pennachioli, Elisabetta, Robert, Caroline, van Akkooi, Alexander A.C.J., Bastholt, Lars, Minisini, Alessandro Marco, Marshall, Ernest, Sales, François, Grob, Jean Jacques, Bechter, Oliver, Schadendorf, Dirk, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Testori, Alessandro

Abstract

Background: Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observation randomised trials demonstrated that a treatment benefit was observed only in patients with an ulcerated melanoma without palpable nodes (hazard ratio [HR] for recurrence-free survival [RFS] was 0.69). This was confirmed by a meta-analysis of 15 adjuvant IFN trials (HR: 0.79). Patients and methods: In the EORTC 18081 trial, sentinel node-negative stage II patients with an ulcerated primary melanoma were 1:1 randomised between pegylated (PEG)-IFNα-2b at 3 μg/kg/week subcutaneously and observation, for 2 years, or until disease recurrence or unacceptable toxicity in spite of dose adjustments to maintain an Eastern Cooperative Oncology Group performance status of 0 or 1. Main end-point was RFS. Secondary end-points included distant metastasis-free survival (DMFS), overall survival, and safety (EudraCT Number: 2009-010273-20). Results: Between February 2013 and January 2017, only 112 patients were randomised, 56 in each arm. The trial was stopped early for lack of recruitment. At a 3.4-year median follow-up, the estimated HR for the PEG-IFNα-2b group compared with the observation group regarding RFS was 0.66 (95% confidence interval [CI]: 0.32–1.37), and the 3-year RFS rate was 80.0% (95% CI: 65.7–88.8%) and 72.9% (95% CI: 58.3–83.0%), respectively. DMFS was prolonged: HR: 0.39 (95% CI: 0.15–0.97), and the 3-year DMFS rate was 90.6% (95% CI: 78.9–96.0%) vs 76.4% (95% CI: 62.1–85.9%). One patient in the PEG-IFNα-2b group died compared with 4 in the observation group. Fifty-four patients started PEG-IFNα-2b treatment, 16 (29%) completed 2 years of treatment, 2 (4%) stopped due to recurrence, 23 (43%) due to toxicity and 14 (25%) due to other reasons. Conclusions: The EORTC 18081 PEG-IFNα-2b randomised trial, observed a similar HR (0.69) for RFS as the previous EORTC trials (0.69). In countries without access to new drugs, adjuvant (PEG)-IFNα-2b treatment is an option for p, SCOPUS: ar.j, DecretOANoAutActif, info:eu-repo/semantics/published

Published
2020

48. Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study

Author

Joly, Pascal, Benichou, Jacques, Lok, Catherine, Hellot, Marie France, Saiag, Philippe, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Labeille, Bruno, Doutre, Marie Sylvie, Gorin, Isabelle, Pauwels, Christine, Chosidow, Olivier, Caux, Frédéric, Estève, Eric, Dutronc, Yves, Sigal, Michèle, Prost, Catherine, Maillard, Hervé, Guillaume, Jean Claude, and Roujeau, Jean Claude

Published
2005

49. Bone Complications of Mastocytosis: A Link between Clinical and Biological Characteristics

Author

Guillaume, Nicolas, Desoutter, Judith, Chandesris, Olivia, Merlusca, Lavinia, Henry, Isabelle, Georgin-Lavialle, Sophie, Barete, Stéphane, Hirsch, Isabelle, Bouredji, Daoud, Royer, Bruno, Gruson, Bérengère, Lok, Catherine, Sevestre, Henri, Mentaverri, Romuald, Brazier, Michel, Meynier, Jonathan, Hermine, Olivier, Marolleau, Jean-Pierre, Kamel, Said, and Damaj, Gandhi

Published
2013
Full Text
View/download PDF

50. Prediction of Survival for Patients wiht Bullous Pemphigoid

Author

Pascal, Joly, Benichou, Jacques, Lok, Catherine, Hellot, Marie France, Saiag, Philippe, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Labeille, Bruno, Doutre, Marie Sylvi, Gorin, Isabelle, Pauwel,Christine, Chosidow, Olivier, Caux, Frederic, Esteve, Eric, Dutronc, Yves, Sigal, Michele, Prost, Catherine, Maillard, Herve, Guillaume, Jean Claude, and Roujeau, Jean Claude

Subjects
Clobetasol -- Dosage and administration, Patients -- Prognosis, Bullous pemphigoid -- Research, Health
Published
2005

Catalog

Books, media, physical & digital resources
See catalog results